News headlines about Illumina (NASDAQ:ILMN) have been trending somewhat positive on Friday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Illumina earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the life sciences company an impact score of 45.106907098522 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern’s rankings:
Shares of Illumina (NASDAQ:ILMN) opened at $230.29 on Friday. The stock has a market capitalization of $33,620.00, a P/E ratio of 46.71, a P/E/G ratio of 3.07 and a beta of 0.79. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.73 and a current ratio of 3.99. Illumina has a 12 month low of $158.02 and a 12 month high of $248.97.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a return on equity of 21.52% and a net margin of 26.56%. The firm’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.85 EPS. equities analysts forecast that Illumina will post 4.59 earnings per share for the current fiscal year.
ILMN has been the subject of a number of recent analyst reports. Citigroup lifted their target price on Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $184.00 to $228.00 in a report on Wednesday, October 25th. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Barclays boosted their price objective on Illumina from $200.00 to $215.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Cowen boosted their price objective on Illumina from $250.00 to $275.00 and gave the company an “outperform” rating in a research report on Monday, January 22nd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $240.61.
In other news, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction that occurred on Saturday, December 29th. The stock was sold at an average price of $217.38, for a total value of $271,725.00. Following the completion of the transaction, the director now owns 8,838 shares in the company, valued at approximately $1,921,204.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $210.59, for a total value of $4,211,800.00. Following the completion of the transaction, the director now owns 536,717 shares of the company’s stock, valued at approximately $113,027,233.03. The disclosure for this sale can be found here. Insiders have sold a total of 132,312 shares of company stock valued at $28,974,614 in the last 90 days. 0.89% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/02/illumina-ilmn-earning-somewhat-positive-media-coverage-report-finds.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.